Tenax Therapeutics has been granted a patent for a method using levosimendan to treat Pulmonary Hypertension with heart failure. The method aims to improve exercise capacity in patients with PH-HFpEF by administering levosimendan intravenously, orally, or subcutaneously. GlobalData’s report on Tenax Therapeutics gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on Tenax Therapeutics, Nanoemulsion cosmetics was a key innovation area identified from patents. Tenax Therapeutics's grant share as of May 2024 was 38%. Grant share is based on the ratio of number of grants to total number of patents.
Treatment of pulmonary hypertension heart failure with levosimendan
A recently granted patent (Publication Number: US11969424B2) outlines a method for enhancing exercise capacity in individuals suffering from Pulmonary Hypertension Heart Failure with preserved Ejection Fraction (PH-HFpEF). The method involves administering levosimendan, its metabolites OR-1896 or OR-1855, or a combination thereof intravenously, orally, or subcutaneously to achieve a minimum 5-meter increase in the six-minute walk distance. The administration can be via IV infusion, oral dosing, or subcutaneous formulation, either as a standalone treatment or in combination with cardiovascular drugs like PDE inhibitors, nitrates, or calcium channel blockers.
Furthermore, the patent details specific dosages, administration methods, and monitoring protocols to ensure the safety and efficacy of the treatment. For instance, the method specifies steady-state blood levels of OR1896 between 0.20 ng/mL to 25.00 ng/mL, with oral dosages ranging from 1-4 mg per day. Importantly, the method aims to improve not only exercise capacity but also the quality of life in patients, as assessed by patient-reported outcome tools like Likert scales. Additionally, the method emphasizes the importance of monitoring for adverse events, such as arrhythmias, and ensuring that the treatment does not result in more serious adverse events compared to a placebo, thus highlighting the safety profile of the proposed intervention.
To know more about GlobalData’s detailed insights on Tenax Therapeutics, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
